 RespireRx Pharmaceuticals OTCQB:RSPI Inc has announced that members of the companys scientific team have published a new article highlighting the potential of novel treatments, including the companys own GABAkine KRM-II-81 for tinnitus, the perception of sound in the absence of external auditory stimulation. Tinnitus affects about 10 to 15 of the general population worldwide and can be markedly debilitating. 